Targeted Drugs for NSCLC Market Report

Global and Region Targeted Drugs for NSCLC Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：140
  • REPORT CODE：GMM958501
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Targeted Drugs for NSCLC market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Targeted Drugs for NSCLCmarket, defines the market attractiveness level of Targeted Drugs for NSCLC market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Targeted Drugs for NSCLC industry, describes the types of Targeted Drugs for NSCLC market, the applications of major players and the market size, and deeply analyzes the current situation of the global Targeted Drugs for NSCLC market and the development prospects and opportunities of Targeted Drugs for NSCLC industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Targeted Drugs for NSCLC market in Chapter 13.

    By Player:

    • ImClone Systems ‎(Eli Lilly)

    • Drug International Limted

    • Mylan

    • Pfizer

    • Novartis

    • Biocon

    • Amgen

    • Teva

    • Allergan

    • OSI Pharmaceuticals

    • AstraZeneca

    • Incepta Pharmaceuticals

    • Cipla

    • Hetero Drugs

    • Fujifilm Kyowa Kirin Biologics

    • Roche

    • Genvio Pharma Limited

    • BeiGene

    • Reliance Lifesciences

    • Beacon Pharma Limited

    • Glenmark Pharmaceuticals

    • ARIAD Pharmaceuticals (Takeda)

    • Boehringer-Ingelheim

    • Celgene Corporation

    • Natco Pharma

    By Type:

    • Target EGFR

    • Target ALK

    • Target HER2

    • Target ROS1

    • Target BRAF

    • Target MEK

    • Target VEGFR2

    • Target VEGF

    • Target MET

    By End-User:

    • Squamous Cell Carcinoma of NSCLC

    • Adenocarcinoma of NSCLC

    • Large Cell Carcinoma of NSCLC

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Targeted Drugs for NSCLC Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Targeted Drugs for NSCLC Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Targeted Drugs for NSCLC Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Targeted Drugs for NSCLC Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Targeted Drugs for NSCLC Market Analysis and Outlook to 2022

    • 7.1 Global Targeted Drugs for NSCLC Consumption (2017-2022)

    • 7.2 United States Targeted Drugs for NSCLC Consumption (2017-2022)

    • 7.3 Europe Targeted Drugs for NSCLC Consumption (2017-2022)

    • 7.4 China Targeted Drugs for NSCLC Consumption (2017-2022)

    • 7.5 Japan Targeted Drugs for NSCLC Consumption (2017-2022)

    • 7.6 India Targeted Drugs for NSCLC Consumption (2017-2022)

    • 7.7 South Korea Targeted Drugs for NSCLC Consumption (2017-2022)

    8 Region and Country-wise Targeted Drugs for NSCLC Market Analysis and Outlook to 2028

    • 8.1 Global Targeted Drugs for NSCLC Consumption Forecast (2022-2028)

    • 8.2 United States Targeted Drugs for NSCLC Consumption Forecast (2022-2028)

    • 8.3 Europe Targeted Drugs for NSCLC Consumption Forecast (2022-2028)

    • 8.4 China Targeted Drugs for NSCLC Consumption Forecast (2022-2028)

    • 8.5 Japan Targeted Drugs for NSCLC Consumption Forecast (2022-2028)

    • 8.6 India Targeted Drugs for NSCLC Consumption Forecast (2022-2028)

    • 8.7 South Korea Targeted Drugs for NSCLC Consumption Forecast (2022-2028)

    9 Global Targeted Drugs for NSCLC Market Outlook by Types and Applications to 2022

    • 9.1 Global Targeted Drugs for NSCLC Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Target EGFR Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Target ALK Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Target HER2 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Target ROS1 Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Target BRAF Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Target MEK Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Target VEGFR2 Consumption and Growth Rate (2017-2022)

      • 9.1.8 Global Target VEGF Consumption and Growth Rate (2017-2022)

      • 9.1.9 Global Target MET Consumption and Growth Rate (2017-2022)

    • 9.2 Global Targeted Drugs for NSCLC Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    10 Global Targeted Drugs for NSCLC Market Outlook by Types and Applications to 2028

    • 10.1 Global Targeted Drugs for NSCLC Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Target EGFR Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Target ALK Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Target HER2 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Target ROS1 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Target BRAF Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Target MEK Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.7 Global Target VEGFR2 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.8 Global Target VEGF Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.9 Global Target MET Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Targeted Drugs for NSCLC Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    11 Global Targeted Drugs for NSCLC Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Targeted Drugs for NSCLC Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Targeted Drugs for NSCLC Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Targeted Drugs for NSCLC Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Targeted Drugs for NSCLC Market Competitive Analysis

    • 14.1 ImClone Systems ‎(Eli Lilly)

      • 14.1.1 ImClone Systems ‎(Eli Lilly) Company Details

      • 14.1.2 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product and Service

    • 14.2 Drug International Limted

      • 14.2.1 Drug International Limted Company Details

      • 14.2.2 Drug International Limted Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Drug International Limted Targeted Drugs for NSCLC Product and Service

    • 14.3 Mylan

      • 14.3.1 Mylan Company Details

      • 14.3.2 Mylan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Mylan Targeted Drugs for NSCLC Product and Service

    • 14.4 Pfizer

      • 14.4.1 Pfizer Company Details

      • 14.4.2 Pfizer Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Pfizer Targeted Drugs for NSCLC Product and Service

    • 14.5 Novartis

      • 14.5.1 Novartis Company Details

      • 14.5.2 Novartis Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Novartis Targeted Drugs for NSCLC Product and Service

    • 14.6 Biocon

      • 14.6.1 Biocon Company Details

      • 14.6.2 Biocon Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Biocon Targeted Drugs for NSCLC Product and Service

    • 14.7 Amgen

      • 14.7.1 Amgen Company Details

      • 14.7.2 Amgen Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Amgen Targeted Drugs for NSCLC Product and Service

    • 14.8 Teva

      • 14.8.1 Teva Company Details

      • 14.8.2 Teva Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Teva Targeted Drugs for NSCLC Product and Service

    • 14.9 Allergan

      • 14.9.1 Allergan Company Details

      • 14.9.2 Allergan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Allergan Targeted Drugs for NSCLC Product and Service

    • 14.10 OSI Pharmaceuticals

      • 14.10.1 OSI Pharmaceuticals Company Details

      • 14.10.2 OSI Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Product and Service

    • 14.11 AstraZeneca

      • 14.11.1 AstraZeneca Company Details

      • 14.11.2 AstraZeneca Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 AstraZeneca Targeted Drugs for NSCLC Product and Service

    • 14.12 Incepta Pharmaceuticals

      • 14.12.1 Incepta Pharmaceuticals Company Details

      • 14.12.2 Incepta Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Product and Service

    • 14.13 Cipla

      • 14.13.1 Cipla Company Details

      • 14.13.2 Cipla Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Cipla Targeted Drugs for NSCLC Product and Service

    • 14.14 Hetero Drugs

      • 14.14.1 Hetero Drugs Company Details

      • 14.14.2 Hetero Drugs Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Hetero Drugs Targeted Drugs for NSCLC Product and Service

    • 14.15 Fujifilm Kyowa Kirin Biologics

      • 14.15.1 Fujifilm Kyowa Kirin Biologics Company Details

      • 14.15.2 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product and Service

    • 14.16 Roche

      • 14.16.1 Roche Company Details

      • 14.16.2 Roche Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Roche Targeted Drugs for NSCLC Product and Service

    • 14.17 Genvio Pharma Limited

      • 14.17.1 Genvio Pharma Limited Company Details

      • 14.17.2 Genvio Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Genvio Pharma Limited Targeted Drugs for NSCLC Product and Service

    • 14.18 BeiGene

      • 14.18.1 BeiGene Company Details

      • 14.18.2 BeiGene Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 BeiGene Targeted Drugs for NSCLC Product and Service

    • 14.19 Reliance Lifesciences

      • 14.19.1 Reliance Lifesciences Company Details

      • 14.19.2 Reliance Lifesciences Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Reliance Lifesciences Targeted Drugs for NSCLC Product and Service

    • 14.20 Beacon Pharma Limited

      • 14.20.1 Beacon Pharma Limited Company Details

      • 14.20.2 Beacon Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Beacon Pharma Limited Targeted Drugs for NSCLC Product and Service

    • 14.21 Glenmark Pharmaceuticals

      • 14.21.1 Glenmark Pharmaceuticals Company Details

      • 14.21.2 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product and Service

    • 14.22 ARIAD Pharmaceuticals (Takeda)

      • 14.22.1 ARIAD Pharmaceuticals (Takeda) Company Details

      • 14.22.2 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.22.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product and Service

    • 14.23 Boehringer-Ingelheim

      • 14.23.1 Boehringer-Ingelheim Company Details

      • 14.23.2 Boehringer-Ingelheim Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.23.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Product and Service

    • 14.24 Celgene Corporation

      • 14.24.1 Celgene Corporation Company Details

      • 14.24.2 Celgene Corporation Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.24.3 Celgene Corporation Targeted Drugs for NSCLC Product and Service

    • 14.25 Natco Pharma

      • 14.25.1 Natco Pharma Company Details

      • 14.25.2 Natco Pharma Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.25.3 Natco Pharma Targeted Drugs for NSCLC Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Targeted Drugs for NSCLC

    • Figure Targeted Drugs for NSCLC Picture

    • Table Global Targeted Drugs for NSCLC Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Targeted Drugs for NSCLC Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Targeted Drugs for NSCLC Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Targeted Drugs for NSCLC Consumption by Country (2017-2022)

    • Figure United States Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)

    • Table Europe Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure China Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Japan Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure India Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure South Korea Targeted Drugs for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Targeted Drugs for NSCLC Consumption Forecast by Country (2022-2028)

    • Figure United States Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Targeted Drugs for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target EGFR Consumption and Growth Rate (2017-2022)

    • Figure Global Target ALK Consumption and Growth Rate (2017-2022)

    • Figure Global Target HER2 Consumption and Growth Rate (2017-2022)

    • Figure Global Target ROS1 Consumption and Growth Rate (2017-2022)

    • Figure Global Target BRAF Consumption and Growth Rate (2017-2022)

    • Figure Global Target MEK Consumption and Growth Rate (2017-2022)

    • Figure Global Target VEGFR2 Consumption and Growth Rate (2017-2022)

    • Figure Global Target VEGF Consumption and Growth Rate (2017-2022)

    • Figure Global Target MET Consumption and Growth Rate (2017-2022)

    • Figure Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Target EGFR Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target ALK Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target HER2 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target ROS1 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target BRAF Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target MEK Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target VEGFR2 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target VEGF Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Target MET Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Targeted Drugs for NSCLC Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Targeted Drugs for NSCLC Export by Region (Top 5 Countries) (2017-2028)

    • Table ImClone Systems ‎(Eli Lilly) (Foundation Year, Company Profile and etc.)

    • Table ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product and Service

    • Table Drug International Limted (Foundation Year, Company Profile and etc.)

    • Table Drug International Limted Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Drug International Limted Targeted Drugs for NSCLC Product and Service

    • Table Mylan (Foundation Year, Company Profile and etc.)

    • Table Mylan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Targeted Drugs for NSCLC Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Targeted Drugs for NSCLC Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Targeted Drugs for NSCLC Product and Service

    • Table Biocon (Foundation Year, Company Profile and etc.)

    • Table Biocon Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Targeted Drugs for NSCLC Product and Service

    • Table Amgen (Foundation Year, Company Profile and etc.)

    • Table Amgen Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Targeted Drugs for NSCLC Product and Service

    • Table Teva (Foundation Year, Company Profile and etc.)

    • Table Teva Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Targeted Drugs for NSCLC Product and Service

    • Table Allergan (Foundation Year, Company Profile and etc.)

    • Table Allergan Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Targeted Drugs for NSCLC Product and Service

    • Table OSI Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table OSI Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table OSI Pharmaceuticals Targeted Drugs for NSCLC Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Targeted Drugs for NSCLC Product and Service

    • Table Incepta Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Incepta Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Incepta Pharmaceuticals Targeted Drugs for NSCLC Product and Service

    • Table Cipla (Foundation Year, Company Profile and etc.)

    • Table Cipla Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cipla Targeted Drugs for NSCLC Product and Service

    • Table Hetero Drugs (Foundation Year, Company Profile and etc.)

    • Table Hetero Drugs Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hetero Drugs Targeted Drugs for NSCLC Product and Service

    • Table Fujifilm Kyowa Kirin Biologics (Foundation Year, Company Profile and etc.)

    • Table Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product and Service

    • Table Roche (Foundation Year, Company Profile and etc.)

    • Table Roche Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Targeted Drugs for NSCLC Product and Service

    • Table Genvio Pharma Limited (Foundation Year, Company Profile and etc.)

    • Table Genvio Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genvio Pharma Limited Targeted Drugs for NSCLC Product and Service

    • Table BeiGene (Foundation Year, Company Profile and etc.)

    • Table BeiGene Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table BeiGene Targeted Drugs for NSCLC Product and Service

    • Table Reliance Lifesciences (Foundation Year, Company Profile and etc.)

    • Table Reliance Lifesciences Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Reliance Lifesciences Targeted Drugs for NSCLC Product and Service

    • Table Beacon Pharma Limited (Foundation Year, Company Profile and etc.)

    • Table Beacon Pharma Limited Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Beacon Pharma Limited Targeted Drugs for NSCLC Product and Service

    • Table Glenmark Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Glenmark Pharmaceuticals Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product and Service

    • Table ARIAD Pharmaceuticals (Takeda) (Foundation Year, Company Profile and etc.)

    • Table ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product and Service

    • Table Boehringer-Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer-Ingelheim Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer-Ingelheim Targeted Drugs for NSCLC Product and Service

    • Table Celgene Corporation (Foundation Year, Company Profile and etc.)

    • Table Celgene Corporation Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene Corporation Targeted Drugs for NSCLC Product and Service

    • Table Natco Pharma (Foundation Year, Company Profile and etc.)

    • Table Natco Pharma Targeted Drugs for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Natco Pharma Targeted Drugs for NSCLC Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US